Tap a claim on the ring to put it at the centre.
← No AI system today reduces either of the two risks that sink most…
17 connected korrents · 15 moments on record from 12 Feb 2010 to 4 Sept 2026.
Everything filed under design
design
Everything filed under taste
taste
Everything filed under AI alignment
AI alignment
Everything filed under simplicity
simplicity Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Read this korrent: No AI system today reduces either of the two risks that sink most drugs in the clinic: picking the wrong target, and human toxicity. No AI system today reduces either of the two risks that sink most drugs in the clinic: picking the wrong target, and human toxicity. Last stated 3 years ago
25 May 2023
DL
Derek Lowe — holds since 2023-05-25 — tap for who they are
Same subject: We have neither the data nor the insight to use machine learning to pick drug targets that succeed in the clinic more often. — tap to centre the map on it We have neither the data nor the insight to use machine learning to pick drug targets that succeed in the clinic more often. Last stated 3 years ago
25 May 2023
DL
Derek Lowe — holds since 2023-05-25 — tap for who they are
Same subject: There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it. — tap to centre the map on it There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it. Last stated 2 years ago
14 Oct 2024
DL
Derek Lowe — holds since 2024-10-14 — tap for who they are
Same subject: Better drug candidates do not shorten clinical trials, because a trial's duration is set by operational and regulatory friction rather than by how good the drug is. — tap to centre the map on it Better drug candidates do not shorten clinical trials, because a trial's duration is set by operational and regulatory friction rather than by how good the drug is. Last stated 6 months ago
28 Feb 2026
RT
Ruxandra Teslo — holds since 2026-02-28 — tap for who they are
Same subject: There is no route to AI alignment or safety that goes around reliability: a system that cannot reliably follow a known algorithm cannot be made safe. — tap to centre the map on it There is no route to AI alignment or safety that goes around reliability: a system that cannot reliably follow a known algorithm cannot be made safe. Last stated a year ago
7 Jun 2025
GM
Gary Marcus — holds since 2025-06-07 — tap for who they are
Same subject: A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. — tap to centre the map on it A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. Last stated 2 years ago
13 May 2024
DL
Derek Lowe — holds since 2024-05-13 — tap for who they are
Same subject: Deep learning is not yet ready for the task that would actually add value in drug development: predicting safety and efficacy in humans. — tap to centre the map on it Deep learning is not yet ready for the task that would actually add value in drug development: predicting safety and efficacy in humans. Last stated 3 years ago
23 Dec 2023
AT
Alex Telford — holds since 2023-12-23 — tap for who they are
Same subject: AI labs tend to downplay safety risks in their public rhetoric even while acting responsibly in practice. — tap to centre the map on it AI labs tend to downplay safety risks in their public rhetoric even while acting responsibly in practice. Last stated 3 days ago
4 Sept 2026
ZM
Zvi Mowshowitz — holds since 2026-09-04 — tap for who they are
Same subject: The human data an AI model would need to predict trial outcomes can only come from trials in people, so the loop runs no faster than the trials themselves. — tap to centre the map on it The human data an AI model would need to predict trial outcomes can only come from trials in people, so the loop runs no faster than the trials themselves. Last stated 6 months ago
28 Feb 2026
RT
Ruxandra Teslo — holds since 2026-02-28 — tap for who they are
Same subject: A blank chat box is lazy: it violates the first rule of a good user experience, that it is obvious what you can do. — tap to centre the map on it A blank chat box is lazy: it violates the first rule of a good user experience, that it is obvious what you can do. Last stated a year ago
12 May 2025
JZ
Julie Zhuo — holds since 2025-05-12 — tap for who they are
Same subject: A company deserves everyone in it, the chief executive included, to spend as much time as possible in their zone of genius — which is an org design problem. — tap to centre the map on it A company deserves everyone in it, the chief executive included, to spend as much time as possible in their zone of genius — which is an org design problem. Last stated a year ago
23 Mar 2025
RV
Rahul Vohra — holds since 2025-03-23 — tap for who they are
Same subject: A computer meant for anyone has to be understandable without a manual, and it has to be friendly. — tap to centre the map on it A computer meant for anyone has to be understandable without a manual, and it has to be friendly. Last stated 3 weeks ago
14 Aug 2026
SK
Susan Kare — holds since 2026-08-14 — tap for who they are
Same subject: After a decade of Swiss minimalism, design is about to swing back to something far more expressive. — tap to centre the map on it After a decade of Swiss minimalism, design is about to swing back to something far more expressive. Last stated 11 months ago
16 Oct 2025
DF
Dylan Field — holds since 2025-10-16 — tap for who they are
Same subject: AI acceleration threatens 'less software': without the constraint of scarce hours, even 37signals will likely build too much. — tap to centre the map on it AI acceleration threatens 'less software': without the constraint of scarce hours, even 37signals will likely build too much. Last stated a month ago
26 Jul 2026
DH
David Heinemeier Hansson — holds since 2026-07-26 — tap for who they are
Same subject: Better design does not mean more design: the most obvious designs are often invisible. — tap to centre the map on it Better design does not mean more design: the most obvious designs are often invisible. Last stated 3 years ago
16 Nov 2023
JZ
Julie Zhuo — holds since 2023-11-16 — tap for who they are
Same subject: A first draft should not be graded good or bad; it is only the material that taste then gets to act on. — tap to centre the map on it A first draft should not be graded good or bad; it is only the material that taste then gets to act on. Last stated a month ago
6 Aug 2026
GS
George Saunders — holds since 2026-08-06 — tap for who they are
Same subject: A lot of people can match a framework for taste; almost nobody can create one, and creating one is the rare skill. — tap to centre the map on it A lot of people can match a framework for taste; almost nobody can create one, and creating one is the rare skill. Last stated 11 months ago
16 Oct 2025
DF
Dylan Field — holds since 2025-10-16 — tap for who they are
Same subject: A product needs a soul, and for that it needs one person of great taste who is its living, breathing aspect and gets furious about every small detail. — tap to centre the map on it A product needs a soul, and for that it needs one person of great taste who is its living, breathing aspect and gets furious about every small detail. Last stated 17 years ago
12 Feb 2010
KS
Karri Saarinen — holds since 2010-02-12 — tap for who they are
At the centre
No AI system today reduces either of the two risks that sink most drugs in the clinic: picking the wrong target, and human toxicity.
Holds DL Derek LoweRead this korrent →
We have neither the data nor the insight to use machine learning to pick drug targets that succeed in the clinic more often.
Holds DL Derek Lowe
There are few clear-cut cases in biopharma today where buying an AI system is obviously worth it.
Holds DL Derek Lowe
Better drug candidates do not shorten clinical trials, because a trial's duration is set by operational and regulatory friction rather than by how good the drug is.
Holds RT Ruxandra Teslo
There is no route to AI alignment or safety that goes around reliability: a system that cannot reliably follow a known algorithm cannot be made safe.
Holds GM Gary Marcus
A compound's AI origin story is not by itself a reason to expect it to do better in the clinic.
Holds DL Derek Lowe
Deep learning is not yet ready for the task that would actually add value in drug development: predicting safety and efficacy in humans.
Holds AT Alex Telford
AI labs tend to downplay safety risks in their public rhetoric even while acting responsibly in practice.
Holds ZM Zvi Mowshowitz
The human data an AI model would need to predict trial outcomes can only come from trials in people, so the loop runs no faster than the trials themselves.
Holds RT Ruxandra Teslo
A blank chat box is lazy: it violates the first rule of a good user experience, that it is obvious what you can do.
Holds JZ Julie Zhuo
A company deserves everyone in it, the chief executive included, to spend as much time as possible in their zone of genius — which is an org design problem.
Holds RV Rahul Vohra
A computer meant for anyone has to be understandable without a manual, and it has to be friendly.
Holds SK Susan Kare
After a decade of Swiss minimalism, design is about to swing back to something far more expressive.
Holds DF Dylan Field
AI acceleration threatens 'less software': without the constraint of scarce hours, even 37signals will likely build too much.
Holds
Better design does not mean more design: the most obvious designs are often invisible.
Holds JZ Julie Zhuo
A first draft should not be graded good or bad; it is only the material that taste then gets to act on.
Holds GS George Saunders
A lot of people can match a framework for taste; almost nobody can create one, and creating one is the rare skill.
Holds DF Dylan Field
A product needs a soul, and for that it needs one person of great taste who is its living, breathing aspect and gets furious about every small detail.
Holds KS Karri Saarinen